Abstract

Search of potent antifilarial drugs has been a major thrust area in tropical medicine research over the decades. Herein, we report 4,7-dimethyl-3,4,7,8-tetrahydro-3λ6-[1,2]thiazino[4,3-f]quinoline-3,3,8-trione (8l) as a new class of antifilarial agent which is extremely potent, with lethality against all the developmental stages (oocyte, microfilaria and adult) of the filarial parasite Setaria cervi. Molecular investigation on its mode of action revealed that 8l is a typical inducer of reactive oxygen species that triggers oxidative stress inside the filarid and further signals induction of apoptosis by activating both intrinsic and extrinsic pathways. Moreover, 8l is also active against Wolbachia, the essential endosymbiont of several human infectious filarids. Selective toxicity against filarial parasites and non-toxic nature in rat model were found as unique traits of 8l to be a future medicine. Taken en masse, this maiden report on a novel quinolone fused cyclic sulfonamide presents a promising therapeutic lead for lymphatic filariasis in future.

Details

Title
Quinolone-fused cyclic sulfonamide as a novel benign antifilarial agent
Author
Mukherjee, Suprabhat 1 ; Joardar, Nikhilesh 1 ; Mondal, Shovan 2 ; Schiefer, Andrea 3 ; Hoerauf, Achim 3 ; Pfarr, Kenneth 4 ; Sinha Babu, Santi P 1 

 Department of Zoology, Visva-Bharati University, Santiniketan, India 
 Department of Chemistry, Syamsundar College, Shyamsundar, India 
 Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany 
 Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany; German Center for Infection Research (DZIF), Bonn, Germany 
Pages
1-10
Publication year
2018
Publication date
Aug 2018
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2088038859
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.